TrialDiabetes, obesity & metabolism2023

Safety, tolerability, pharmacodynamics and pharmacokinetics following once-daily doses of BI 187004, an inhibitor of 11 beta-hydroxysteroid dehydrogenase-1, over 28 days in patients with type 2 diabetes mellitus and overweight or obesity.

Susanna Bianzano et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.